Cargando…
Diagnostic and Therapeutic Pathways of Intramuscular Myxoma
Intramuscular myxomas (IMMs) are benign tumors. Evidence regarding diagnostic and therapeutic pathways is rare, and guidelines do not exist due to their low incidence. The aim of this study was a retrospective analysis at a university cancer center and the interdisciplinary re-evaluation of the indi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316518/ https://www.ncbi.nlm.nih.gov/pubmed/35885479 http://dx.doi.org/10.3390/diagnostics12071573 |
_version_ | 1784754834119852032 |
---|---|
author | Reiter, Alonja Trumm, Katharina Ballhause, Tobias M. Weiss, Sebastian Frosch, Karl-Heinz Korthaus, Alexander Bechler, Ulrich Duprée, Anna Luebke, Andreas Bannas, Peter Schlickewei, Carsten W. Priemel, Matthias H. |
author_facet | Reiter, Alonja Trumm, Katharina Ballhause, Tobias M. Weiss, Sebastian Frosch, Karl-Heinz Korthaus, Alexander Bechler, Ulrich Duprée, Anna Luebke, Andreas Bannas, Peter Schlickewei, Carsten W. Priemel, Matthias H. |
author_sort | Reiter, Alonja |
collection | PubMed |
description | Intramuscular myxomas (IMMs) are benign tumors. Evidence regarding diagnostic and therapeutic pathways is rare, and guidelines do not exist due to their low incidence. The aim of this study was a retrospective analysis at a university cancer center and the interdisciplinary re-evaluation of the individual diagnostic and therapeutic procedures. Overall, 38 patients were included in the study. IMMs occurred mostly in middle-aged women. At the time of first consultation, 57.9% had few symptoms or were asymptomatic. In 92.1% of the cases, the tumor was localized in the extremities. The lower extremity was affected in 73.7%. The average size of IMMs was 5.0 cm. The proximally located tumors in the gluteus, thighs, and upper arms were significantly larger (p = 0.02) than the distally-located tumors in the forearms and lower legs. An MRI was performed in 97.4%. Based on imaging, an IMM was suspected in 5.6% by radiologists and in 54.1% by musculoskeletal surgeons. An incision biopsy was performed in 68.4% and led in 100.0% to the right histopathological diagnosis. In total, 89.5% of IMMs were resected. Postoperative complications requiring revision occurred in 8.8%. Recurrences or degenerations of IMMs were not reported in any of these cases. |
format | Online Article Text |
id | pubmed-9316518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93165182022-07-27 Diagnostic and Therapeutic Pathways of Intramuscular Myxoma Reiter, Alonja Trumm, Katharina Ballhause, Tobias M. Weiss, Sebastian Frosch, Karl-Heinz Korthaus, Alexander Bechler, Ulrich Duprée, Anna Luebke, Andreas Bannas, Peter Schlickewei, Carsten W. Priemel, Matthias H. Diagnostics (Basel) Article Intramuscular myxomas (IMMs) are benign tumors. Evidence regarding diagnostic and therapeutic pathways is rare, and guidelines do not exist due to their low incidence. The aim of this study was a retrospective analysis at a university cancer center and the interdisciplinary re-evaluation of the individual diagnostic and therapeutic procedures. Overall, 38 patients were included in the study. IMMs occurred mostly in middle-aged women. At the time of first consultation, 57.9% had few symptoms or were asymptomatic. In 92.1% of the cases, the tumor was localized in the extremities. The lower extremity was affected in 73.7%. The average size of IMMs was 5.0 cm. The proximally located tumors in the gluteus, thighs, and upper arms were significantly larger (p = 0.02) than the distally-located tumors in the forearms and lower legs. An MRI was performed in 97.4%. Based on imaging, an IMM was suspected in 5.6% by radiologists and in 54.1% by musculoskeletal surgeons. An incision biopsy was performed in 68.4% and led in 100.0% to the right histopathological diagnosis. In total, 89.5% of IMMs were resected. Postoperative complications requiring revision occurred in 8.8%. Recurrences or degenerations of IMMs were not reported in any of these cases. MDPI 2022-06-28 /pmc/articles/PMC9316518/ /pubmed/35885479 http://dx.doi.org/10.3390/diagnostics12071573 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Reiter, Alonja Trumm, Katharina Ballhause, Tobias M. Weiss, Sebastian Frosch, Karl-Heinz Korthaus, Alexander Bechler, Ulrich Duprée, Anna Luebke, Andreas Bannas, Peter Schlickewei, Carsten W. Priemel, Matthias H. Diagnostic and Therapeutic Pathways of Intramuscular Myxoma |
title | Diagnostic and Therapeutic Pathways of Intramuscular Myxoma |
title_full | Diagnostic and Therapeutic Pathways of Intramuscular Myxoma |
title_fullStr | Diagnostic and Therapeutic Pathways of Intramuscular Myxoma |
title_full_unstemmed | Diagnostic and Therapeutic Pathways of Intramuscular Myxoma |
title_short | Diagnostic and Therapeutic Pathways of Intramuscular Myxoma |
title_sort | diagnostic and therapeutic pathways of intramuscular myxoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316518/ https://www.ncbi.nlm.nih.gov/pubmed/35885479 http://dx.doi.org/10.3390/diagnostics12071573 |
work_keys_str_mv | AT reiteralonja diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT trummkatharina diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT ballhausetobiasm diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT weisssebastian diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT froschkarlheinz diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT korthausalexander diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT bechlerulrich diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT dupreeanna diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT luebkeandreas diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT bannaspeter diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT schlickeweicarstenw diagnosticandtherapeuticpathwaysofintramuscularmyxoma AT priemelmatthiash diagnosticandtherapeuticpathwaysofintramuscularmyxoma |